Edwards Lifesciences Corporation’s Stock Price Skyrockets to $68.54, Marking a Robust 6.20% Uptick

Edwards Lifesciences Corporation (EW)

68.54 USD +4.00 (+6.20%) Volume: 10.21M

Edwards Lifesciences Corporation’s stock price surged by +6.20% this trading session, reaching $68.54 with a robust trading volume of 10.21M, despite a year-to-date percentage change of -10.11%, indicating a potential turnaround for EW’s stock performance.

Latest developments on Edwards Lifesciences Corporation

Today, Edwards Lifesciences saw its stock price target lowered to $66 from $77 by Canaccord, leading to a decrease in investor confidence. However, call volume for the company remains above normal and directionally bullish, indicating potential positive movement in the near future. The recent approval of TTVR has caused the stock to soar, but challenges still remain. Despite trading 6.2% higher, shareholders who invested three years ago are currently in the red. With various price target cuts and ratings being held, including a lowered target to $75 from $85 by RBC Capital, the company is facing a transition year outlook. Piper Sandler maintains a Neutral rating on Edwards Lifesciences shares, showing mixed opinions on the stock’s performance.

A look at Edwards Lifesciences Corporation Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Edwards Lifesciences has a mixed long-term outlook. While the company scores moderately in areas such as value, growth, resilience, and momentum, it falls short in the dividend category. This suggests that Edwards Lifesciences may not be the most attractive option for investors seeking regular income through dividends.

However, with strong scores in value, growth, resilience, and momentum, Edwards Lifesciences shows promise for long-term growth and stability in the cardiovascular disease treatment market. The company’s focus on products such as tissue replacement heart valves, hemodynamic monitoring devices, and pharmaceuticals positions it well for continued success in the global market for cardiovascular treatments.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma